Erratum: Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care. (Current Medical Research and Opinion (2005) 21, 7 (1131-1137) DOI: 10.1185/030079905X50651);Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care

Current Medical Research and Opinion

Volumn 21, Issue 7, 2005, Pages 1131-1137

  O'Brien, T P ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Cataract treatment strategy; Cystoid macular edema; Nonsteroidal antiinflammatory drugs

Indexed keywords

BROMFENAC; CORTICOSTEROID; DICLOFENAC; FLUOROMETHOLONE; FLURBIPROFEN; INDOMETACIN; KETOROLAC TROMETAMOL; LOTEPREDNOL ETABONATE; NEPAFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE ACETATE; SUPROFEN; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; CATARACT EXTRACTION; CLINICAL TRIAL; DIABETIC RETINOPATHY; DRUG ACCUMULATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENTIATION; DRUG SAFETY; DRUG USE; EYE INFLAMMATION; EYE IRRITATION; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; KERATOLYSIS; MIOSIS; MONOTHERAPY; MULTICENTER STUDY; PATIENT CARE; PHOTOPHOBIA; POSTOPERATIVE INFLAMMATION; POSTOPERATIVE PAIN; PRACTICE GUIDELINE; PUNCTATE KERATITIS; RETINA MACULA CYSTOID EDEMA; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN DEFECT; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; WOUND HEALING IMPAIRMENT;

EID: 22744455811     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X61893     Document Type: Erratum

References (51)

1. Flach AJ. Topical nonsteroidal antiinflammatory drugs in ophthalmology. Int Ophthalmol Clin 2002;42:1-11
2. Heier JS, Topping TM, Baumann W, et al. Ketorolac versus prednisolone versus combination therapy in treatment of acute pseudophakic cystoid macular edema. Am Acad Ophthalmology 2000;107:2034-38
3. Flach AJ. Heier et al. Treatment of acute CME: Discussion: ketorolac vs. prednisolone vs. combination therapy in the treatment of acute CME. Ophthalmology 2000;107:2039
4. Solomon KD, Cheetham JK, DeGryse R, et al. Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery. Ophthalmology 2001;108:331-7
5. Snyder RW. Preventing CME after cataract surgery. Ophthalmology management [online]. Available at: http://www. ophmanagement.com/article.aspx? article=&loc=archive\2003\ april\allergan\0403allergan3.htm [accessed 04/28/05]
6. Flach AJ, Jampol LM, Weinberg D, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol 1991;112:514-9
7. Solomon LD. Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema [Flurbiprofen-CME Study Group I]. J Cataract Refract Surg 1995;21:73-81
8. Miyake K, Masuda K, Shirato S, et al. Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial. Jpn J Ophthalmol 2000;44:58-67
9. Rho DS. Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. J Cataract Refract Surg 2003;29:2378-84
10. Weisz JM, Bressler NM, Bressler SB, Schachat AP. Ketorolac treatment of pseudophakic cystoid macular edema identified more than 24 months after cataract extraction. Ophthalmology 1999;106:1656-9
11. Flach AJ. Nonsteroidal anti-inflammatory drugs. In: Tasman W, editor. Duane's foundations of clinical ophthalmology. Philadelphia: Lippincott; 1994. p. 1-32
12. Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol 1992;36:259-84
13. Roberts CW, Brennan KM. A comparison of topical diclofenac with prednisolone for postcataract inflammation. Arch Ophthalmol 1995;113:725-7
14. Hsu JK, Johnston WT, Read RW, et al. Histopathology of corneal melting associated with diclofenac use after refractive surgery. J Cataract Refract Surg 2003;29:250-6
15. Snyder RW, Siekert RW, Schwiegerling J, et al. Acular as a single agent for use as an antimiotic and anti-inflammatory in cataract surgery. J Cataract Refract Surg 2000;26:1225-7
16. McColgin AZ, Raizman MB. Efficacy of topical Voltaren in reducing the incidence of postoperative cystoid macular edema. Invest Ophthalmol Vis Sci 1999;40(Suppl):289
17. Guzek JP, Holm M, Cotter JB, et al. Risk factors for intraoperative complications in 1000 extracapsular cataract cases. Ophthalmology 1987;94:461-6
18. Stewart R, Grosserode R, Cheetham JK, et al. Efficacy and safety profile of ketorolac 0.5% ophthalmic solution in the prevention of surgically induced miosis during cataract surgery. Clin Ther 1999;21:723-32
19. Roberts CW. Comparison of diclofenac sodium and flurbiprofen for inhibition of surgically induced miosis. J Cataract Refract Surg 1996;22(Suppl 1):780-7
20. Samudre SS, Lattanzio Jr FA, Williams PB, Sheppard Jr JD. Comparison of topical steroids for acute anterior uveitis. J Ocul Pharmacol Ther 2004;20:533-47
21. Lu KL, Wee WR, Sakamoto T, McDonnell PJ. Comparison of in vitro antiproliferative effects of steroids and nonsteroidal anti-inflammatory drugs on human keratocytes. Cornea 1996;15:185-90
22. Nguyen KD, Lee DA. Effects of steroids and nonsteroidal antiinflammatory agents on human ocular fibroblast. Invest Ophthalmol Vis Sci 1992;33:2693-701
23. Nguyen KD, Lee DA. In vitro evaluation of antiproliferative potential of topical cyclo-oxygenase inhibitors in human Tenon's fibroblasts. Exp Eye Res 1993;57:97-105
24. Nassaralla B, Szerenyi K, Wang XW, et al. Effect of diclofenac on corneal haze after photorefractive keratectomy in rabbits. Ophthalmology 1995;102:469-74
25. Simone JN, Pendelton RA, Jenkins JE. Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery. J Cataract Refract Surg 1999;25:599-704
26. Flach AJ, Dolan BJ, Donahue ME, et al. Comparative effects of ketorolac 0.5% or diclofenac 0.1% ophthalmic solutions on inflammation after cataract surgery. Am J Ophthalmology 1998;105:1775-9
27. El-Harazi SM, Ruiz RS, Feldman RM, et al. A randomized double-masked trial comparing ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, and prednisolone acetate 1% in reducing post-phacoemulsification flare and cells. Ophthalmic Surg Lasers 1998;29:439-544
28. Roberts CW. Pretreatment with topical diclofenac sodium to decrease postoperative inflammation. Ophthalmology 1996;103:636-9
29. Nelson ML, Martidis A. Managing cystoid macular edema after cataract surgery. Curr Opin Ophthalmol 2003;14:39-43
30. Heier, JS. Preventing post-cataract extraction CME: early identification of patients at risk and prophylactic treatment may avert vision loss. Ophthalmology Management October 2004;63-72
31. Gills JP. Voltaren associated with medication keratitis [letter]. J Cataract Refract Surg 1994;20:110
32. Sher NA, Krueger RR, Teal R, Jans RG. Role of topical corticosteroids and nonsteroidal anti-inflammatory drugs in the etiology of stromal infiltrates after excimer photorefractive keratectomy. J Refract Corneal Surg 1994;10:587-8
33. Probst LEV, Machat JJ. Corneal subepithelial infiltrates following photorefractive keratectomy [letter]. J Cataract Refract Surg 1996;22:281
34. Shimazaki J, Saito H, Yang HY, et al. Persistent epithelial defect following penetrating keratoplasty: an adverse effect of diclofenac eye drops. Cornea 1995;14:623-7
35. Congdon NG, Schein OD, von Kulajta P, et al. Corneal complications associated with topical ophthalmic use of nonsteroidal antiinflammatory drugs. J Cataract Refract Surg 2001;27:622-31
36. O'Brien TP, Li QJ, Sauerburger F, et al. The role of matrix metalloproteinases in ulcerative keratolysis associated with perioperative diclofenac use. Ophthalmology 2001;108:656-9
37. Reviglio VE, Rana TS, Li QJ, et al. Effects of topical nonsteroidal antiinflammatory drugs on the expression of matrix metalloproteinases in the cornea. J Cataract Refract Surg 2003;29:989-97
38. Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Saf 2002;25:233-50
39. Gamache DA, Graff G, Brady MT, et al. Nepafenac, a unique nonsteroidal pro-drug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of antiinflammatory efficacy. Inflammation 2000;24:357-70
40. Sher NA, Frantz JM, Talley A, et al. Topical diclofenac in the treatment of ocular pain after excimer photorefractive keratectomy. Refract Cornea Surg 1993;9:425-36
41. McGee DH, Heaton JD, Gruebbel MM, et al. Ocular Effects of nepafenac ophthalmic suspension in New Zealand White rabbits undergoing partial corneal incisions. Paper presented at: Annual meeting of the Association for Research in Vision and Ophthalmology, May 03, 2005, Fort Lauderdale, FL
42. Walker LM, Rice RL, Heaton JD, et al. Ocular effects of nepafenac ophthalmic suspension following three months of topical ocular administration to Cynomolgus monkeys. Paper presented at: Annual meeting of the Association for Research in Vision and Ophthalmology, May 03, 2005, Fort Lauderdale, FL
43. Heaton J, Hiddemen JW, Hackett RB, et al. Ocular effects of nepafenac ophthalmic suspension following six months of topical ocular administration to pigmented rabbits. Paper presented at: Annual meeting of the Association for Research in Vision and Ophthalmology, May 03, 2005, Fort Lauderdale, FL
44. Kern TS, Miller C, Du YP, et al. Topical administration of nepafenac inhibits the early stages of diabetic retinopathy. Paper presented at: Annual meeting of the Association for Research in Vision and Ophthalmology, May 03, 2005, Fort Lauderdale, FL
45. Song Q, McCollum GW, Macrorie-Fairweather R, et al. Nepafenac metabolite, amfenac, inhibits VEGF induced phosphorylation of ERK in human retinal microvascular endothelial cells. Paper presented at: Annual meeting of the Association for Research in Vision and Ophthalmology, May 03, 2005, Fort Lauderdale, FL
46. Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal pro-drug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation 2000;24:371-84
47. Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation 2003;27:281-91
48. Mishima H, Masuda K, Miyake K, et al. The putative role of prostaglandins in cystoid macular edema. Prog Clin Biol Res 1989;31:251-64
49. Takahashi K, Saishin Y, Saishin Y, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci 2003;44:409-15
50. Lane SS, Modi SS, Holland EJ, et al. Nepafenac ophthalmic suspension 0.1% before and after surgery for postoperative anterior segment inflammation. Paper presented at: American Society of Cataract and Refractive Surgery, April 14, 2005, Washington, DC
51. Donnenfeld ED, Holland EJ, Stewart R, Grillone LR. Topical xibrom 0.1% investigational NSAID to decrease inflammation after cataract surgery. Paper presented at: American Society of Cataract and Refractive Surgery; April 14, 2005, Washington, DC